BTX BioTime, Inc. Common Stock

3.46
0  -4%
Previous Close 3.59
Open 3.51
Price To book 3.09
Market Cap 355.59M
Shares 102,772,000
Volume 407,905
Short Ratio 14.24
Av. Daily Volume 370,477

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
AST-OPC1 - SCiStar
Cervical spinal cord injury
Pivotal trial data due by mid-2017.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 2 second cohort underway. Data due May 7-11, 2017 at ARVO conference.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. BioTime, Inc.: Trading close to its 50 day moving average. Good buy?
  2. BioTime, Inc. is trading above its 50 day moving average : BTX-US : March 22, 2017
  3. BioTime, Inc. :BTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  4. BioTime, Inc. :BTX-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
  5. BioTime, Inc.: Strong price momentum but will it sustain?
  6. BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : March 20, 2017
  7. BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
  8. BIOTIME INC Files SEC form 8-K, Results of Operations and Financial Condition
  9. BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
  10. Q4 2016 BioTime Inc Earnings Release - After Market Close
  11. Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
  12. BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
  13. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : March 8, 2017
  14. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : March 7, 2017
  15. BioTime, Inc. : Undervalued relative to peers, but don’t ignore the other factors
  16. BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : February 24, 2017
  17. BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
  18. BioTime Reports $56M Non-Cash Gain On Deconsolidation
  19. BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session
  20. BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary

SEC Filings

  1. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17695569
  2. 8-K - Current report 17695098
  3. 8-K - Current report 17623241
  4. SC 13D/A (Amend) - General statement of acquisition of beneficial ownership 17622242
  5. 8-K - Current report 17614749
  6. 8-K - Current report 17595391
  7. 424B5 - Prospectus (Rule 424(b)(5)) 17594793
  8. 8-K - Current report 17587711
  9. 424B5 - Prospectus (Rule 424(b)(5)) 17587684
  10. SC 13D/A (Amend) - General statement of acquisition of beneficial ownership 17521094